- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07941778
Ivarmacitinib Treat PMR (ESI-PMR)
Efficacy and Safety of Ivarmacitinib for Polymyalgia Rheumatica (ESI-PMR): A 52-Week Open-Label, Randomized, Controlled Clinical Trial
To evaluate the efficacy of the combination of Ivarmacitinib and short-term glucocorticoid induction for remission and rapid discontinuation of glucocorticoids in the treatment of Polymyalgia rheumatica (PMR) , and to compare the differences in the proportion of patients in remission at weeks 24 between the experimental group and control group.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
PMR is a common inflammatory disorder in older adults (aged >50 years), characterized by pain and stiffness in the neck, shoulder girdle, and pelvic girdle. Systemic glucocorticoid administration is the current standard of care, achieving rapid control of inflammation and symptom alleviation. However, standard regimens require prolonged administration (at least 12 months) and are associated with a high rate of relapse during steroid tapering. In this vulnerable population with a high burden of baseline chronic comorbidities (e.g., osteoporosis, diabetes, cardiovascular disease), sustained glucocorticoid use frequently leads to severe adverse effects, such as steroid-induced osteoporosis, peptic ulceration, hyperglycemia, glaucoma, opportunistic infections, and metabolic dysregulation. Consequently, there is an urgent need to explore safer, more effective, and more accessible therapeutic strategies.
Ivarmacitinib, a highly selective JAK1 inhibitor, is approved for rheumatoid arthritis and ankylosing spondylitis, but remains unapproved for PMR. Thus, this protocol represents an investigator-initiated off-label study. Accumulated evidence indicates that JAK1 inhibition holds substantial potential for controlling PMR disease activity and facilitating steroid tapering. To address the current lack of high-level clinical evidence, this study was initiated to assess the 52-week efficacy and safety of ivarmacitinib in patients with PMR.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Weiqian Chen Dr. Chen, Doctor
- Numero di telefono: 860571-87233418
- Email: cwq678@zju.edu.cn
Backup dei contatti dello studio
- Nome: Xinxin Han Dr. Han, Doctor
- Numero di telefono: 860571-87233418
- Email: hxx1992@126.com
Luoghi di studio
-
-
Zhejiang
-
Anji, Zhejiang, Cina
- Anji People's Hospital
-
Contatto:
- Chunyan Chen Dr. Chen
- Numero di telefono: +8618167257305
- Email: 375709261@qq.com
-
Haining, Zhejiang, Cina
- Haining Kanghua Hospital
-
Contatto:
- Jiantao Sun Dr. Sun
- Numero di telefono: +8615967333501
- Email: 5598338@qq.com
-
Hangzhou, Zhejiang, Cina
- the First Affiliated Hospital, Zhejiang University School of Medicine
-
Contatto:
- Weiqian Chen Dr. Chen, Doctor
- Numero di telefono: 860571-87233418
- Email: cwq678@zju.edu.cn
-
Huzhou, Zhejiang, Cina
- Huzhou First People's Hospital
-
Contatto:
- Min Ding Dr. Ding
- Numero di telefono: +8615805827300
- Email: 1943902345@qq.com
-
Wenzhou, Zhejiang, Cina
- Wenzhou People's Hospital
-
Contatto:
- Suxian Lin Dr. Lin
- Numero di telefono: 8613957741565
- Email: 4268945@qq.com
-
Yiwu, Zhejiang, Cina
- the Fourth Affiliated Hospital, Zhejiang University School of Medicine
-
Contatto:
- Jie Chang Dr. Chang
- Numero di telefono: 8613705790575
- Email: changjie7311@163.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- patients who fulfilled the 2012ACR/EULAR criteria for PMR;
- Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS > 10,
- Adults age 50-88, Weight 45-85Kg,
- ESR>40mm/h or CRP >50mg/L(5mg/dl),
- Informed consent.
Exclusion Criteria:
- Patients with known allergies to Ivarmacitinib, prednisone or methylprednisolone,
- Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
- Patients with severe osteoarthritis,
- Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
- Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,
- Patients with abnormal liver function (ALT/AST 2 times higher); Moderate to severe renal impairment (glomerular filtration rate <60); hyperlipidemia not improved by lipid-lowering drugs,
- Pregnant or lactating women,
- Patients with a history of malignancy who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),
- Patients with previous visual field disorder or single eye dysfunction, cataract patients,
- Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,
- For patients with abnormal blood routine, lymphocytes <500/mm3 or ANC <1000/mm3 or HGB < 90g/L,
- Patients with active bleeding and peptic ulcer,
- Have used biological agents or added azathioprine, FK506 within 1 month before enrollment,
- Those who have participated in other drug clinical trials within 4 weeks
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Ivarmacitinib
Withdrawal of prednisone within 8 weeks: 15mg daily for 2 weeks, 10mg daily for 4 weeks, 5mg daily for 2 weeks, then discontinue; Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks. |
Withdrawal of prednisone within 8 weeks. Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks. |
|
Comparatore attivo: Prednisone
Prednisone 15mg daily was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-8 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 10 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. |
The dose of Prednisone was gradually tapered. Once relapse occurred, the dose increased to the pre-relapse dose. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients in remission at weeks 24
Lasso di tempo: at weeks 24
|
Proportion of patients in remission at weeks 24 |
at weeks 24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients in remission at weeks 52
Lasso di tempo: at weeks 52
|
Proportion of patients in remission at weeks 52 |
at weeks 52
|
|
PMR-AS score at weeks 24
Lasso di tempo: at weeks 24
|
PMR-AS score: CRP (mg/dL)+Patient self-evaluation (0-10 visual scale)+ Physician global assessment (0-10 Visual Scale)+[morning stiffness (min) x0.1]+ EUL (0-3). |
at weeks 24
|
|
CRP at weeks 24
Lasso di tempo: at weeks 24
|
CRP at weeks 24 |
at weeks 24
|
|
ESR at weeks 24
Lasso di tempo: at weeks 24
|
ESR at weeks 24 |
at weeks 24
|
|
Relapse rate within 52 weeks
Lasso di tempo: within 52 weeks
|
Relapse rate within 52 weeks |
within 52 weeks
|
|
Relapse times within 52 weeks
Lasso di tempo: within 52 weeks
|
Relapse times within 52 weeks |
within 52 weeks
|
|
Cumulative dose of prednisone within 52 weeks
Lasso di tempo: within 52 weeks
|
Cumulative dose of prednisone within 52 weeks |
within 52 weeks
|
|
Cumulative dose of MTX within 52 weeks
Lasso di tempo: within 52 weeks
|
Cumulative dose of MTX within 52 weeks |
within 52 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Jin Lin, Prof., First Affiliated Hospital of Zhejiang University
Pubblicazioni e link utili
Pubblicazioni generali
- Camellino D, Dejaco C, Martini F, Cosso R, Bianchi G. Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases. Reumatismo. 2025 Feb 13;77(1). doi: 10.4081/reumatismo.2024.1796. Epub 2024 Oct 28.
- Liu X, Xu L, Zhao C, Liu S, Sun L, Yang L, Xu X, Wu R, Liu X, Zhang J, Xu S, Zhu P, Chen H, Wang X, Lin C, Lin J, Zhan F, Wei H, Huang Q, Liu H, Ma X, Shi G, Lu Y, Geng X, Jiang Z, Zhang N, Tang K, Zhang R, Zhao Y, Xue L, Song S, Shi X, Zhang Z, Liu P, Wang H, Li Z. Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial. Arthritis Rheumatol. 2025 Nov;77(11):1512-1523. doi: 10.1002/art.43238. Epub 2025 Aug 5.
- Xu X, Wei H, Liu L, Yang R, Shi Q, Pang D. Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial. Front Pharmacol. 2025 Nov 20;16:1710434. doi: 10.3389/fphar.2025.1710434. eCollection 2025.
- Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, He X, Wu R, Yang L, Liu H, Duan X, Xu S, Luo H, Liu J, Xie Q, Mi C, Chen L, Zhang N, Gong H, Zhu J, Li Y, Wei H, Qian L, Wang J, Shi X, Jin H, Jiang Z, Xie X, Zhan F, Geng X, Zheng Z, Du Z, Dong G, Sun Y, Zeng X. Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis. 2025 Feb;84(2):188-200. doi: 10.1136/ard-2024-226385. Epub 2025 Jan 3.
- Ma X, Yang F, Wu J, Xu B, Jiang M, Sun Y, Sun C, Yu Y, Xu D, Xiao L, Ren C, Chen C, Ye Z, Liang J, Lin J, Chen W. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med. 2023 Jun 29;20(6):e1004249. doi: 10.1371/journal.pmed.1004249. eCollection 2023 Jun.
- Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel BJ, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, Saraux A. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA. 2022 Sep 20;328(11):1053-1062. doi: 10.1001/jama.2022.15459.
- Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016 Jun 14;315(22):2442-58. doi: 10.1001/jama.2016.5444.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IIT20260100C-R1
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Due to the policies of the country, it is not possible to directly share the personal data of the subjects. If the researchers are interested, they can contact the relevant person via email to obtain the summarized data.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .